Expanded Role for Immunotherapy to Treat Endometrial Cancer

Expanded Role for Immunotherapy to Treat Endometrial Cancer - NCI

Immunotherapy is likely to become a much more common treatment for women with advanced endometrial cancer, following the release of results from two large ...

Imfinzi, Keytruda Approved for Some Endometrial Cancers - NCI

Role of Immunotherapy in Treating Endometrial Cancer Expands ... Adding immune checkpoint inhibitors to standard treatment provides substantial ...

Adding immunotherapy to first-line treatment of advanced and ...

Immunotherapy added to chemotherapy improves disease-free and overall survival in advanced and metastatic endometrial cancer.

Immunotherapy in endometrial cancer: new scenarios on the horizon

PARP is an enzyme that catalyzes the poly ADP-ribosylation of proteins involved in DNA repair and has proven effective in treatment of ovarian cancers with ...

Immune Checkpoint Inhibitors Revolutionize Endometrial Cancer ...

Immune checkpoint inhibitors (ICI), such as pembrolizumab (Keytruda) and dostarlimab-gxly (Jemperli), include high affinity, high specificity, and humanized ...

Immunotherapy Produces 'Unprecedented Results' for Advanced ...

The transformative impact of two groundbreaking studies focused on immunotherapy to treat advanced endometrial cancer may signal a shift in ...

Advanced endometrial cancer—The next generation of treatment

The updated 2023 FIGO staging of endometrial cancer was reviewed. The panel then described the role of upfront immunotherapy for the treatment of advanced ...

Immunotherapy for Uterine Cancer - Cancer Research Institute

Immunotherapy for uterine (endometrial) cancer is an emerging area of research and treatment, especially for patients with advanced cases.

The Evolving Landscape of Immunotherapy in Uterine Cancer

Current data suggest that active and/or passive immunotherapy may be promising for the treatment of endometrial cancer.

Endometrial Cancer Indications Expanded for Pembrolizumab

The FDA approved pembrolizumab (Keytruda), in combination with chemotherapy, for certain patients with endometrial cancer.

Evolving Treatment Landscape in Endometrial Cancer

Recently, clinical trials have shown promising results for immunotherapy and targeted therapies in patients with advanced or metastatic endometrial cancer.

Adding immunotherapy to first-line treatment of advanced and ...

Immunotherapy added to chemotherapy improves disease-free and overall survival in advanced and metastatic endometrial cancer.

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression- ...

Immunotherapy for Endometrial Cancer - American Cancer Society

Pembrolizumab can be used by itself to treat advanced endometrial cancers, typically after other treatments have been tried, if surgery or ...

Second-Line Options Expand With the Use of Immunotherapy in ...

Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this ...

A Review of Immune Checkpoint Blockade Therapy in Endometrial ...

In 2019, the FDA granted accelerated approval for lenvatinib in combination with pembrolizumab for the treatment of advanced endometrial cancer ...

approved for adults with certain types of advanced endometrial cancer

KEYTRUDA is a prescription medicine used to treat a kind of uterine cancer called advanced endometrial carcinoma. KEYTRUDA may be used with the chemotherapy ...

FDA Expands Pembrolizumab Approval for Endometrial Cancer

The US Food and Drug Administration (FDA) has expanded the indication for pembrolizumab (Keytruda, Merck) to include the use of the targeted immunotherapy ...

Immunotherapy in endometrial cancer: rationale, practice and ...

Immune checkpoint inhibitors (ICIs), cancer vaccines, adoptive cell transfer (ACT), and lymphocyte-promoting cytokines are the main immunotherapy methods.

Merck Receives Positive EU CHMP Opinions for KEYTRUDA ...

“At Merck, we are deeply committed to expanding the role of KEYTRUDA to improve outcomes for more patients facing difficult-to-treat gynecologic ...